TY - JOUR AU - Askarian, M. AU - Yadollahi, M. AU - Kuochak, F. AU - Danaei, M. AU - Vakili, V. AU - Momeni, M. PY - 2011 DA - 2011// TI - Precautions for health care workers to avoid hepatitis B and C virus infection JO - The international journal of occupational and environmental medicine VL - 2 ID - Askarian2011 ER - TY - STD TI - Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO. http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed 15 Sept 2017. UR - http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en ID - ref2 ER - TY - JOUR AU - Sarrazin, C. AU - Berg, T. AU - Buggisch, P. AU - Dollinger, M. M. AU - Hinrichsen, H. AU - Hofer, D. H. PY - 2015 DA - 2015// TI - Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C S3 guideline hepatitis C addendum JO - Z Gastroenterol VL - 53 UR - https://doi.org/10.1055/s-0034-1399322 DO - 10.1055/s-0034-1399322 ID - Sarrazin2015 ER - TY - JOUR AU - Ingiliz, P. AU - Christensen, S. AU - Kimhofer, T. AU - Hueppe, D. AU - Lutz, T. AU - Schewe, K. AU - Busch, H. AU - Schmutz, G. AU - Wehmeyer, M. H. AU - Boesecke, C. PY - 2016 DA - 2016// TI - Sofosbuvir and Ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-Monoinfected and HIV-HCV-Coinfected individuals: results from the German hepatitis C cohort (GECCO-01) JO - Clinical infectious diseases: an official publication of the Infectious Diseases Society of America VL - 63 UR - https://doi.org/10.1093/cid/ciw567 DO - 10.1093/cid/ciw567 ID - Ingiliz2016 ER - TY - STD TI - Lubel J, Strasser S, Stuart KA, Dore G, Thompson A, Pianko S et al. Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir +/- ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study. Antivir Ther. 2017;22(8):699–710. https://doi.org/10.3851/IMP3168. ID - ref5 ER - TY - JOUR AU - Sarrazin, C. AU - Berg, T. AU - Ross, R. S. AU - Schirmacher, P. AU - Wedemeyer, H. AU - Neumann, U. PY - 2010 DA - 2010// TI - Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection JO - Zeitschrift fur Gastroenterologie VL - 48 UR - https://doi.org/10.1055/s-0028-1110008 DO - 10.1055/s-0028-1110008 ID - Sarrazin2010 ER - TY - JOUR AU - Westbrook, R. H. AU - Dusheiko, G. PY - 2014 DA - 2014// TI - Natural history of hepatitis C JO - J Hepatol VL - 61 UR - https://doi.org/10.1016/j.jhep.2014.07.012 DO - 10.1016/j.jhep.2014.07.012 ID - Westbrook2014 ER - TY - JOUR AU - Gonzalez-Grande, R. AU - Jimenez-Perez, M. AU - Gonzalez Arjona, C. AU - Mostazo, T. J. PY - 2016 DA - 2016// TI - New approaches in the treatment of hepatitis C JO - World Journal of Gastroenterology : WJG VL - 22 UR - https://doi.org/10.3748/wjg.v22.i4.1421 DO - 10.3748/wjg.v22.i4.1421 ID - Gonzalez-Grande2016 ER - TY - STD TI - Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y et al. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. Liver Int. 2016;36:817–26. https://doi.org/10.1111/liv.13071. ID - ref9 ER - TY - JOUR AU - Nienhaus, A. AU - Kesavachandran, C. AU - Wendeler, D. AU - Haamann, F. AU - Dulon, M. PY - 2012 DA - 2012// TI - Infectious diseases in healthcare workers - an analysis of the standardised data set of a German compensation board JO - J Occup Med Toxicol. VL - 7 UR - https://doi.org/10.1186/1745-6673-7-8 DO - 10.1186/1745-6673-7-8 ID - Nienhaus2012 ER - TY - JOUR AU - Dulon, M. L. AU - Lisiak, B. AU - Wendeler, D. AU - Nienhaus, A. PY - 2014 DA - 2014// TI - Data from the institution for statutory accident insurance and prevention in the health and welfare services JO - Zbl Arbeitsmed VL - 65 UR - https://doi.org/10.1007/s40664-015-0030-3 DO - 10.1007/s40664-015-0030-3 ID - Dulon2014 ER - TY - JOUR AU - Westermann, C. AU - Dulon, M. AU - Wendeler, D. AU - Nienhaus, A. PY - 2016 DA - 2016// TI - Hepatitis C among healthcare personnel: secondary data analyses of costs and trends for hepatitis C infections with occupational causes JO - J Occup Med Toxicol VL - 11 UR - https://doi.org/10.1186/s12995-016-0142-5 DO - 10.1186/s12995-016-0142-5 ID - Westermann2016 ER - TY - STD TI - Swart E, Bitzer EM, Gothe H, Harling M, Hoffmann F, Horenkamp-Sonntag D et al. [A Consensus German Reporting Standard for Secondary Data Analyses, Version 2 (STROSA-STandardisierte BerichtsROutine fur SekundardatenAnalysen)]. Gesundheitswesen (Bundesverband der Ärzte des Öffentlichen Gesundheitsdienstes (Germany)). 2016. ID - ref13 ER - TY - STD TI - Cohen J, Cohen P, West SG, Aiken LS. Applied multiple regression/correlation analysis for the behavioral sciences (3rd ed.). Mahwah: Lawrence Erlbaum; 2003. ID - ref14 ER - TY - JOUR AU - Nuno Solinis, R. AU - Arratibel Ugarte, P. AU - Rojo, A. AU - Sanchez, G. Y. PY - 2016 DA - 2016// TI - Value of treating all stages of chronic hepatitis C: a comprehensive review of clinical and economic evidence JO - Infectious diseases and therapy VL - 5 UR - https://doi.org/10.1007/s40121-016-0134-x DO - 10.1007/s40121-016-0134-x ID - Nuno Solinis2016 ER - TY - JOUR AU - Stahmeyer, J. T. AU - Krauth, C. AU - Bert, F. AU - Pfeiffer-Vornkahl, H. AU - Alshuth, U. AU - Huppe, D. PY - 2016 DA - 2016// TI - Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial JO - J Viral Hepat VL - 23 UR - https://doi.org/10.1111/jvh.12471 DO - 10.1111/jvh.12471 ID - Stahmeyer2016 ER - TY - JOUR AU - Backus, L. I. AU - Belperio, P. S. AU - Shahoumian, T. A. AU - Loomis, T. P. AU - Mole, L. A. PY - 2016 DA - 2016// TI - Comparative effectiveness of ledipasvir/sofosbuvir +/− ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir +/− ribavirin in 6961 genotype 1 patients treated in routine medical practice JO - Aliment Pharmacol Ther VL - 44 UR - https://doi.org/10.1111/apt.13696 DO - 10.1111/apt.13696 ID - Backus2016 ER - TY - JOUR AU - Lawitz, E. AU - Makara, M. AU - Akarca, U. S. AU - Thuluvath, P. J. AU - Preotescu, L. L. AU - Varunok, P. PY - 2015 DA - 2015// TI - Efficacy and safety of Ombitasvir, Paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis JO - Gastroenterology VL - 149 UR - https://doi.org/10.1053/j.gastro.2015.07.001 DO - 10.1053/j.gastro.2015.07.001 ID - Lawitz2015 ER - TY - JOUR AU - Zeuzem, S. PY - 2017 DA - 2017// TI - Treatment options in hepatitis C JO - Dtsch Arztebl Int VL - 114 ID - Zeuzem2017 ER - TY - JOUR AU - Zimmermann, R. AU - Kollan, C. AU - Ingiliz, P. AU - Mauss, S. AU - Schmidt, D. AU - Bremer, V. PY - 2017 DA - 2017// TI - Real-world treatment for chronic hepatitis C infection in Germany: analyses from drug prescription data, 2010–2015 JO - J Hepatol VL - 67 UR - https://doi.org/10.1016/j.jhep.2017.01.024 DO - 10.1016/j.jhep.2017.01.024 ID - Zimmermann2017 ER - TY - JOUR AU - Schäfer, M. AU - Schwaiger, M. PY - 2003 DA - 2003// TI - Incidence, Pathoetiology and treatment of interferon-α induced neuro-psychiatric side Effetcs JO - Fortschr Neurol Psychiatr VL - 71 UR - https://doi.org/10.1055/s-2003-42188 DO - 10.1055/s-2003-42188 ID - Schäfer2003 ER - TY - JOUR AU - Slim, J. AU - Afridi, M. S. PY - 2012 DA - 2012// TI - Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV JO - Infect Dis Clin N Am VL - 26 UR - https://doi.org/10.1016/j.idc.2012.08.006 DO - 10.1016/j.idc.2012.08.006 ID - Slim2012 ER - TY - STD TI - 14th Congress for Hospital Hygiene 2018, Berlin, March 18–21, 2018. Lecture on March 19 at 2.45 p.m.: [Vision 'zero infections' - can this be achieved in view of the temporal trend in occupational infections? A contribution to the discussion from the perspective of BGW - A. Nienhaus (Hamburg)]. https://www.congress-compact.de/pdf/2018_03_18-21_DGKH_Jahreskongress_Hauptprogramm.pdf. Accessed 10 Apr 2018. UR - https://www.congress-compact.de/pdf/2018_03_18-21_DGKH_Jahreskongress_Hauptprogramm.pdf ID - ref23 ER - TY - STD TI - Ltd. LHP. THE ECO-HEP REPORT. A macroeconomic overview of viral hepatitis C in Germany https://www.leberhilfe-projekt.de/das-eco-hep-modell.html: Leberhilfe Projekt gUG (Liver Help Project Ltd.); Babette Herder and Achim Kautz; [2.8.2017]. Accssed 15 Sept 2017. UR - https://www.leberhilfe-projekt.de/das-eco-hep-modell.html: ID - ref24 ER - TY - STD TI - Warpakowski A. Hepatitis C: Elimination in Europa möglich. Dtsch Ärztebl International.113(21):-20-. ID - ref25 ER - TY - STD TI - WHO. GLOBAL HEALTH SECTOR STRATEGY ON VIRAL HEPATITIS 2016–2021 [updated 2.8.2017; cited Juni 2016]. Available from: http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/. Accessed 17 May 2018. UR - http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/ ID - ref26 ER - TY - STD TI - Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015;385(9973):1124–1135. ID - ref27 ER -